| |
Discover how our oncology-focused clinical development solutions help you move from milestone to milestone with speed and precision. Let’s talk smarter trials. Request more information.
|
|
Today’s Big NewsMay 20, 2025 |
| By Nick Paul Taylor Pfizer has joined the PD-1xVEGF bispecific gold rush. The Big Pharma is paying 3SBio $1.25 billion upfront for ex-China rights to a clinical candidate, establishing itself as a challenger to BioNTech, Merck & Co. and Summit Therapeutics in a scorching-hot area of immuno-oncology. |
|
|
|
By James Waldron A dementia-focused transatlantic venture capital initiative has secured $269 million in commitments for its second fund. |
By Gabrielle Masson Fierce 15 nominations are open! We're searching for the most innovative, resourceful and visionary biotechs leading the way through the industry's mercurial conditions. |
Sponsored by Bridge Bank, a division of Western Alliance Bank, Member FDIC Here’s how experienced banking partnerships create value beyond traditional lending and why industry-specific expertise matters in navigating the complex life sciences landscape. |
By Ben Adams CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the next-gen thrombotic disease asset SRSD107. |
Sponsored by AGC Biologics Tech transfer is conceptually a straightforward process, but it is fraught with minutiae and unknowns that can introduce delays, unplanned costs, and batch failures. |
By James Waldron RegenXBio will fill its coffers with up to $250 million by monetizing more royalty rights for Novartis-partnered Zolgensma as well as anticipated payments linked to a gene therapy nearing approval and a third candidate in development. |
Sponsored by Ohio Discovery Corridor Cleveland Diagnostics redefines cancer detection with new technology developed at the Cleveland Clinic in the heart of the Ohio Discovery Corridor. |
By Darren Incorvaia Tourmaline Bio’s lead candidate sparkled in a new mid-stage data drop, prepping the biotech to develop the former Pfizer asset further in a pair of cardiovascular indications. |
By Gabrielle Masson Blueprint Medicines is revising a pact with VantAI again, this time adding a focus for historically “undruggable” targets and prioritizing new target-effector pairs that could be used to develop molecular glue therapeutics. |
By Fraiser Kansteiner BioNTech plans to invest up to 1 billion pounds sterling ($1.3 billion) over the next decade to beef up its R&D base in the U.K. The project will include the construction of two new research centers in the country, plus a U.K. headquarters for the German biotech in London, which will also house an artificial intelligence “hub." |
By Gabrielle Masson Despite hitting a clinical “milestone,” Prime Medicine is shelving its sole clinical-stage genetic medicine and laying off an undisclosed number of staffers. |
By Darren Incorvaia Hot on the heels of a $150 million fundraise, gene therapy outfit Atsena Therapeutics has debuted data showing that the company’s eye disease candidate led to no serious treatment-related adverse events and improved the structure and function of the retina. |
By Eric Sagonowsky President Donald Trump's recent Executive Order on drug prices applies to "all brand products across all markets that do not currently have generic or biosimilar competition," the HHS said in a Tuesday press release. |
By Angus Liu With the FDA approval of the first blood-based test to help diagnose Alzheimer’s disease, Eisai and Biogen’s acceleration plan for Leqembi has been set in motion. But bending the Leqembi sales curve may still take time, a Mizuho analyst argued. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce Pharma breaks down President Donald Trump’s executive order targeting drug prices and what it could mean for the industry as broader policy shifts unfold. |
|
|---|
|
|
|
Thursday, May 29, 2025 | 11am ET / 8am PT While the use of precision therapies continues to expand, precision oncology drug development is facing increasing costs and complexity. It is more important than ever to implement strategies and solutions for maximizing efficiencies throughout the drug development process. Join us to learn more.
|
|
| WhitepaperDon’t delay your gene transfer trial’s start-up timeline by gaining the latest insights from WCG’s case study on the power of a seamless Institutional Review Board (IRB) and Institutional Biosafety Committee (IBC) review process. Sponsored by: WCG |
| WhitepaperLearn how the SpyLock service can offer fast bispecific generation, reduce workload, and accelerate candidate selection. Sponsored by: Bio-Rad |
| WhitepaperWe interviewed 24 Medical Affairs leaders on the critical success factors for building a Best Practice Medical Affairs organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
